GC 2107

Drug Profile

GC 2107

Alternative Names: CB02-0133; GC-2107; GC4401; GCC-2107; GCC-4401; GCC-4401C; I Fxa - LegoChem Biosciences; LCB-02-0133; Nokxaban

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LegoChem Biosciences
  • Developer Green Cross; LegoChem Biosciences
  • Class Anticoagulants; Antithrombotics; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Embolism; Stroke; Venous thromboembolism

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Embolism(Prevention, In volunteers) in USA (PO, Capsule)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Stroke(Prevention, In volunteers) in USA (PO, Capsule)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Venous thromboembolism(Prevention, In volunteers) in USA (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top